Developing a solution to human metapneumovirus, have developed diagnostics, vaccines, antibodies, and antivirals

ViroNovative BV is focused on addressing human Metapneumovirus (hMPV) through a comprehensive approach that includes the development of diagnostics, vaccines, antibodies, and antiviral treatments. Established in 2002, the company collaborates closely with the Department of Viroscience at Erasmus MC, leveraging the expertise of nearly 200 virologists to enhance its research and product development efforts. With a robust network of industrial partners, ViroNovative has secured 20 active licenses related to hMPV patents, which underscores its commitment to generating innovative solutions and economic value in the field of virology.

The clinical implications of hMPV infection are significant, as it can lead to a range of respiratory illnesses, particularly in vulnerable populations such as young children, the elderly, and immunocompromised individuals. Symptoms can vary from mild upper respiratory issues, akin to a common cold, to more severe conditions like bronchitis and pneumonia, which may necessitate hospitalization. The diverse clinical manifestations of hMPV infection, including gastrointestinal symptoms and other complications, highlight the need for effective diagnostic and therapeutic strategies, which ViroNovative is actively pursuing through its research and development initiatives.

Netherlands

ViroNovative BV, established in 2002, is dedicated to providing a complete solution to human Metapneumovirus (hMPV), a virus discovered in 2001 at the Department of Viroscience, Erasmus MC. To this end, ViroNovative is co-developing diagnostics, vaccines, antibodies and antivirals for the detection, prevention and treatment of hMPV infection. With a strong network of industrial partners (to date 20 licenses on the hMPV patents are active) we generate new products and economic value.

ViroNovative BV

Company Details